Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis by Byun Esther, Caillier Stacy J, Montalban Xavier, Villoslada Pablo, Fernández Oscar, Brassat David, Comabella Manuel, Wang Joanne, Barcellos Lisa F, Baranzini Sergio E, Oksenberg Jorge R in Archives of neurology (2008). PubMed

Abstract

To identify promising candidate genes linked to interindividual differences in the efficacy of interferon beta therapy. Recombinant interferon beta therapy is widely used to reduce disease activity in multiple sclerosis (MS). However, up to 50% of patients continue to have relapses and worsening disability despite therapy.

[ hide abstract ]

Discussed In Paper